Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Condition:   InfectionInterventions:   Drug: Pegylated Interferon Alfa 2a;   Drug: Ribavirin;   Drug: TelaprevirSponsors:   M.D. Anderson Cancer Center;   Vertex Pharmaceuticals IncorporatedTerminated - verified February 2015

Source: ClinicalTrials.gov - March 27, 2013 Category: Research Source Type: clinical trials